for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

BRIEF-Regenxbio Announces First FDA Approval Of A Gene Therapy Based On Its Proprietary Nav Technology Platform

May 24 (Reuters) - Regenxbio Inc:

* REGENXBIO ANNOUNCES FIRST FDA APPROVAL OF A GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM

* REGENXBIO INC - ADDITIONAL APPROVALS FOR GENE THERAPY BASED ON ITS PROPRIETARY NAV® TECHNOLOGY PLATFORM ANTICIPATED IN EUROPE AND JAPAN IN 2019 Source text for Eikon: Further company coverage:

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up